NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. NV-387’s proposed mechanism targets viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as health authorities work to contain the outbreak, underscoring the need for effective treatments. NanoViricides emphasized that NV-387 is designed to be a broad-spectrum antiviral drug, with plans to develop it as a treatment for RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s lead drug candidate is currently being advanced toward Phase II human clinical trials.
According to the press release, NV-387 does not encapsulate remdesivir; however, the company also has a separate drug candidate, NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, NV-CoV-2-R could be an approvable drug if safety is comparable. NanoViricides is also developing drugs against a range of viral diseases, including herpes, influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola.
The company’s platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific mechanisms for human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
As with any drug development, NanoViricides noted that the path to commercialization is lengthy and requires substantial capital. There can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and view the full press release at https://ibn.fm/mm3Z5.
